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Abstract
Introduction: Ifosfamide is a chemotherapy agent infrequently associated with liver toxicity. To the best of our
knowledge, this report is the first to describe serious liver toxicity associated with ifosfamide used in combination
with doxorubicin that caused acute but fully reversible liver failure and encephalopathy. This report reviews the
possible mechanisms by which ifosfamide causes this adverse effect.
Case report: A 61-year-old Caucasian woman who presented with an inoperable right neck mass due to synovial
sarcoma was treated with standard-dose ifosfamide and doxorubicin. Within 24 hours of completing the first cycle
of chemotherapy, she developed significant derangements in liver function, with a 250-fold increase in
transaminase and associated synthetic function impairment and encephalopathy. No other causes of liver failure
were identified. Both biochemical tests and encephalopathy were reversed after supportive management and
treatment with N-acetylcysteine. No liver toxicity was observed with subsequent cycles of chemotherapy with
doxorubicin alone.
Conclusion: This case highlights the possibility that chemotherapy agents can cause rare and idiosyncratic
toxicities, so physicians must be vigilant for drug reactions, especially when patients do not respond to usual
treatment.
Introduction
Ifosfamide is an alkylating cytotoxic agent used in the
treatment of a variety of cancers, including germ cell
tumors, sarcomas, lymphoma and lung cancer. It is used
alone or, more frequently, in combination with other
drugs, such as in the present case, with doxorubicin.
The dose-limiting toxicities of ifosfamide are myelosup-
pression and urotoxicity. Effects on the liver are infre-
quently seen, and significant toxicity has been suggested
in only one case report so far [1]. Manufacturers suggest
a 3% incidence of hepatic function derangement with
the use of ifosfamide as a single agent on the basis of 30
single-agent studies of 2070 patients in the published lit-
erature [2]. Table 1 shows a list of adverse drug reac-
tions listed on the product package insert. This case
report describes the use of ifosfamide in a patient with
synovial sarcoma, a common type of soft tissue sarcoma
with notable sensitivity to chemotherapy [3].
Case presentation
A 61-year-old Caucasian woman with a diagnosis of
synovial sarcoma in the right lung apex initially pre-
sented with a six-month history of increasing scapular
pain, for which she was undergoing physiotherapy. Dur-
ing this time, a neck mass developed which progressed
to vocal hoarseness, right-sided Horner’s syndrome and
arm swelling. She was an otherwise well woman with no
significant medical history or drug history.
She underwent a computed tomography (CT)-guided
biopsy, which led to the diagnosis of synovial sarcoma.
Staging investigations confirmed a 10 cm × 8 cm × 9
cm mass extending from the carina to the right side of
the neck and causing tracheal deviation and compres-
sion of the internal jugular vein. There was no metasta-
sis seen on the staging CT scan or on the positron
emission tomography (PET) scan.
The localized but extensive tumor was clearly inoper-
able, and the treatment plan was to initiate chemother-
apy and subsequently consolidate this treatment with
radiotherapy or surgery. She was commenced on the
standard chemotherapy combination of ifosfamide at 3
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2/day for three days and doxorubicin at 20 mg/m
2/
day for three days. Her body surface area was 1.6 m
2,s o
she received a total of 4800 mg/day ifosfamide infused
over four hours. Other medications co-administered
with the chemotherapy regimen were dexamethasone,
ondansetron and metoclopramide as anti-emetics and
mesna for the prevention of urothelial toxicity.
Within 24 hours of completing the three-day treat-
ment, the patient became drowsy and complained of
hallucinations. This occurrence was thought to be a
manifestation of ifosfamide neurotoxicity, a well-estab-
lished side effect. Methylene blue at 50 mg three times
daily was administered intravenously as the standard
antidote.
Despite this treatment, her confusion persisted and
blood tests revealed that at day one after finishing che-
motherapy, she had developed a dramatic deterioration
in her liver function tests, with a 250-fold rise in alanine
aminotransferase (ALT) as well as abnormal liver syn-
thetic function and renal function (Table 2). The
development of encephalopathy within seven days of the
onset of jaundice constitutes hyperacute liver failure.
S h eh a dam o d e s t l ye l e v a t e da m m o n i al e v e la t7 7μM/l
(normal, < 50) accompanying the encephalopathy. These
findings were attributed to ifosfamide use on the basis
of the temporal relationship and the subsequent normal-
ization after drug withdrawal. Apart from her mental
state, her clinical examination was unremarkable. In par-
ticular, there was no fever, rash or arthralgia to suggest
a hypersensitivity drug reaction. The clinical features of
drug-induced liver failure are difficult to differentiate
from acute liver failure of other etiologies.
To exclude other causes of acute liver failure, a full
liver screen was carried out, all of which produced nega-
tive results (ceruloplasmin, auto-antibodies, ferritin, viral
hepatitis screen, a-fetoprotein and paracetamol levels).
An ultrasound of the liver showed normal venous flow
with no focal lesions, fatty infiltration or underlying
chronic liver pathology. A brain CT scan excluded intra-
cerebral causes of acute confusion and showed a normal
brain without significant cerebral edema, which may be
associated with higher grades of hepatic encephalopathy.
All concurrent medications were stopped. These drugs
included cocodamol 30/500 (a combination of codeine
phosphate and acetaminophen), Oramorph (oral mor-
phine sulfate) and amitriptyline to prevent any addi-
tional sedative effects. The patient also regularly took
pantoprazole and multivitamins, which were withheld.
Proton pump inhibitors have been reported rarely or
very rarely to produce jaundice and hepatitis. However,
the patient had not previously experienced any deleter-
ious effects from taking these medications.
The patient was treated with N-acetylcysteine at
150 mg/kg over 16 hours, which commenced on the
Table 1 Significant adverse effects of ifosfamide
a
Adverse reaction Incidence, %
Alopecia 83%
Nausea/vomiting 58%
Hematuria 46%
Gross hematuria 12%
Central nervous system toxicity 12%
Infection 8%
Renal impairment 6%
Liver dysfunction 3%
Phlebitis 2%
Fever 1%
aAdverse effects are as listed on the product package insert.
Table 2 Blood results and number of days post-completion of chemotherapy
a
Number of
days post-
chemotherapy
ALT, IU/l
(normal
range, < 40)
AST, IU/l
(normal
range, 10 to
42)
ALP, IU/l
(normal range,
24 to 110)
GGT, IU/l
(normal
range, < 35)
Br, μM/l
(normal
range, < 17)
INR
(normal
=1 )
Albumin, g/l
(normal range,
30 to 50)
Creatinine, μM/l
(normal range,
54 to 98)
Baseline 12 75 19 11 39 64
1 621 71 38 1.9 29 76
2 3086 5209 77 27 24 2.2 29 107
3 1894 1539 70 35 22 1.6 27 127
4 1203 383 72 52 21 1.3 26 122
5 792 123 76 83 27 1.2 27 112
6 630 68 85 102 23 1.1 27 101
7 443 39 88 103 25 1.1 26 87
8 309 30 86 95 19 1.1 28 84
9 229 25 94 88 18 1.0 30 78
10 148 20 82 85 13 1.0 29 89
11 102 16 84 78 12 1.0 27 93
12 81 100 77 8 1.0 29 86
aIU, international normalized ratio; ALT, alanine transferase; AST, aspartate transaminase; ALP, alkaline phosphatase; GGT, g-glutamyl transpeptidase; Br, bilirubin.
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until her hepatic function and enzyme tests improved.
Although N-acetylcysteine is the antidote for paraceta-
mol overdose, there is evidence for its use in other
forms of drug-induced acute liver failure to reduce mor-
tality [4]. She was also given lactulose regularly at 20 ml
twice daily to reduce encephalopathy. She remained
hemodynamically stable throughout this period and did
not require high-dependency care or mechanical
ventilation.
She had biochemical improvements after commencing
treatment (and stopping the offending chemotherapy
agent). Her level of encephalopathy gradually receded to
mild somnolence, and by about 10 days post-treatment
she felt completely back to normal. Of note is that her
transaminase levels had not yet normalized and her
alkaline phosphatase level had not peaked at that point.
After recovery, the patient subsequently received che-
motherapy with doxorubicin alone and experienced no
further derangements in liver function. She received the
same regimen of anti-emetics as for the first cycle (dexa-
methasone, ondansetron and metoclopramide), so
although ondansetron has been associated with transient
elevation of liver enzymes as a rare side effect, these
medications were not thought to be to blame for the
hepatotoxicity observed. Mesna, which was not required
with the omission of ifosfamide, has no reported side
effects on the liver recorded in the British National For-
mulary or in a survey of over 100 participants in con-
trolled trials [2].
The patient demonstrated a good partial response
after six cycles of doxorubicin treatment and then
underwent consolidation radiotherapy to the right lung
apex. She is being followed up every three months with
alternating chest X-rays and chest CT and is symptoma-
tically well.
Discussion
Liver injury during chemotherapy may not always reflect
direct hepatotoxicity of anti-cancer drugs. It may be due
to or exacerbated by tumor disease and progression,
immunosuppression, concurrent medical problems,
nutritional deficits or parenteral feeding and polyphar-
macy, which can affect susceptibility to acute liver
insult. Most hepatotoxic reactions associated with che-
motherapy agents are idiosyncratic, due to immunologi-
cal reactions or variations in host metabolic response,
and not dose-dependent [5]. Immune-mediated drug
reactions tend to show a latency of one to five weeks
and are associated with hypersensitivity features such as
fever, rash, eosinophilia and autoantibody positivity.
Metabolism-mediated reactions lack these features.
Biopsy of the liver in acute drug reactions may show
cytolytic or cholestatic features or evidence of vascular
injury [6]. While certain drugs are known to cause spe-
cific types of injury, the type of injury in idiosyncratic
drug reactions can be of variable morphology. A liver
biopsy can be performed when drug-induced liver injury
is suspected, along with imaging and laboratory investi-
gations to exclude other causes, but the key to the diag-
nosis is the temporal relationship of drug exposure and
the patient’s clinical picture. A validated diagnostic scale
has been developed to aid in the diagnosis of drug-
induced liver injury. It is based on the time correlation
with drug use and withdrawal, response to re-exposure,
previous reports of liver injury and exclusion of alterna-
tive causes [6].
While ifosfamide and its structurally related alkylating
agent, cyclophosphamide, are both activated in the liver
by P450 oxidases, they are uncommon hepatic toxins
[7], and it is suggested they can be used safely in
patients with abnormal liver function without the need
to modify dosage [5]. One paper has suggested a dose
reduction of 25% for bilirubin > 3 mg/dl [8]. A few
reports of hepatotoxicity associated with the use of
cyclophosphamide have been published [5]. This adverse
reaction is thought to be due to the metabolites of
cyclophosphamide, particularly acrolein, which, unu-
sually, is a dose-dependent effect. Cyclophosphamide in
high doses, such as those used in bone marrow pre-con-
ditioning, can also lead to veno-occlusive disease [6].
While ifosfamide also produces acrolein as a metabolite,
it has not been reported to be associated with hepato-
toxicity. One report has described a patient with breast
cancer and extensive liver metastases, but no pre-treat-
ment deterioration in liver function, who developed
acute liver failure and subsequently died after treatment
with ifosfamide and docetaxel, although there was also a
rise in uric acid and tumor lysis could have contributed
to the patient’s death [1]. The present case report is the
first recorded instance of significant liver toxicity asso-
ciated with ifosfamide use in combination with
doxorubicin.
Ifosfamide is associated with more commonly known
side effects, which can be explained by its metabolism
(Figure 1). It causes myelosuppression which is dose-
dependent and ameliorated by the use of growth factors
such as granulocyte colony-stimulating factor (G-CSF).
G-CSF was not used in our case. Urotoxicity is mani-
fested through hemorrhagic cystitis due to acrolein,
which is prevented by vigorous hydration and co-admin-
istration of mesna, which reacts with acrolein. Nephro-
toxicity as characterized by Fanconi syndrome and
glomerular damage is more common in children and is
much more prevalent in association with ifosfamide
than with cyclophosphamide [7]. Approximately 45% of
the therapeutic dose of ifosfamide is metabolized into
chloroacetaldehyde (CAA) via N-dechloroethylation,
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CAA [9]. Thus, the nephrotoxicity of ifosfamide has
been attributed to this metabolite. Chloroacetaldehyde is
also thought to be responsible for ifosfamide-induced
encephalopathy. Structurally, it is related to chloralhy-
drate, a known hypnotic. Methylene blue may counter-
act the oxidation reactions in the mitochondria that are
linked to CAA and thought to be responsible for ence-
phalopathy [10].
It is possible that ifosfamide use in susceptible indivi-
duals may cause hepatotoxicity via acrolein. However, if
acrolein is implicated, then mesna should have a role in
protecting against liver injury. Our patient did not have
any evidence of urothelial toxicity, such as hematuria, to
indicate a failure of mesna in neutralizing the acrolein
produced. However, an idiosyncratic drug reaction to
ifosfamide may also involve a completely different path-
way due to individual metabolic variance. Measurement
of ifosfamide metabolites requires specific liquid chro-
matography techniques and is not readily available out-
side research studies, but in this case the demonstration
of an unusually high level of acrolein, for example, may
have been of clinical value to elucidate the mechanism
of idiosyncratic hepatotoxicity.
The main treatment of drug-induced liver toxicity is
withdrawal of the offending agent. Most patients recover
completely; therefore, management involves providing
supportive care in the interim. Some patients may
require plasmapheresis. Corticosteroids have no estab-
lished role, but may be used in suppressing the hyper-
sensitivity features of immunological idiosyncratic
reactions [6]. N-acetylcysteine may help by replenishing
liver glutathione stores [4]. Ultimately, acute liver failure
may necessitate transplantation.
Conclusion
Idiosyncratic drug reactions are rare and unpredictable.
This case report describes the previously undocumented
hepatotoxic potential of ifosfamide, but more impor-
tantly alerts clinicians to the potential adverse effects
associated with any medication. In the case of ifosfa-
mide-induced liver toxicity, regular monitoring of liver
enzymes and other blood parameters, along with
patients’ clinical conditions, allows early detection of
unusual side effects. The most important management
strategy in patients with drug-induced liver injury is to
stop treatment with the offending agent. Close monitor-
ing and early involvement of a specialist unit are recom-
mended, as the patient’s failure to improve may
necessitate intensive care input and transplantation.
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Figure 1 Simplified diagram of ifosfamide metabolism.
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